CN113248494A - 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物 - Google Patents

四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物 Download PDF

Info

Publication number
CN113248494A
CN113248494A CN202110308336.4A CN202110308336A CN113248494A CN 113248494 A CN113248494 A CN 113248494A CN 202110308336 A CN202110308336 A CN 202110308336A CN 113248494 A CN113248494 A CN 113248494A
Authority
CN
China
Prior art keywords
compound
formula
cancer
hydrogen
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110308336.4A
Other languages
English (en)
Chinese (zh)
Inventor
D·C·迈尔斯
P·J·库什纳
C·L·哈蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Olema Pharmaceuticals Inc
Original Assignee
Olema Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olema Pharmaceuticals Inc filed Critical Olema Pharmaceuticals Inc
Publication of CN113248494A publication Critical patent/CN113248494A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN202110308336.4A 2015-10-01 2016-09-29 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物 Pending CN113248494A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235900P 2015-10-01 2015-10-01
US62/235,900 2015-10-01
CN201680067297.0A CN108366996B (zh) 2015-10-01 2016-09-29 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680067297.0A Division CN108366996B (zh) 2015-10-01 2016-09-29 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物

Publications (1)

Publication Number Publication Date
CN113248494A true CN113248494A (zh) 2021-08-13

Family

ID=58427985

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110308336.4A Pending CN113248494A (zh) 2015-10-01 2016-09-29 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物
CN201680067297.0A Active CN108366996B (zh) 2015-10-01 2016-09-29 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680067297.0A Active CN108366996B (zh) 2015-10-01 2016-09-29 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物

Country Status (26)

Country Link
US (5) US10292971B2 (enExample)
EP (2) EP3355884B1 (enExample)
JP (3) JP6776348B2 (enExample)
KR (2) KR20240142622A (enExample)
CN (2) CN113248494A (enExample)
AU (4) AU2016331065B2 (enExample)
BR (2) BR112018006121B1 (enExample)
CA (1) CA3000410A1 (enExample)
CL (1) CL2018000827A1 (enExample)
CY (1) CY1124669T1 (enExample)
DK (1) DK3355884T3 (enExample)
ES (1) ES2881398T3 (enExample)
HR (1) HRP20211124T1 (enExample)
HU (1) HUE055321T2 (enExample)
IL (3) IL310489A (enExample)
LT (1) LT3355884T (enExample)
MX (2) MX382269B (enExample)
NZ (1) NZ779654A (enExample)
PL (1) PL3355884T3 (enExample)
PT (1) PT3355884T (enExample)
RS (1) RS62133B1 (enExample)
RU (2) RU2745742C1 (enExample)
SI (1) SI3355884T1 (enExample)
SM (1) SMT202100433T1 (enExample)
UA (1) UA122346C2 (enExample)
WO (1) WO2017059139A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032311B1 (ru) 2014-12-18 2019-05-31 Ф. Хоффманн-Ля Рош Аг Тетрагидро-пиридо[3,4-b]индоловые модуляторы эстрогеновых рецепторов и их применение
HUE055321T2 (hu) * 2015-10-01 2021-11-29 Olema Pharmaceuticals Inc Tetrahidro-1H-pirido[3,4-b]indol anti-ösztrogén hatóanyagok
CA3008020C (en) 2015-12-09 2024-02-20 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
ES2842579T3 (es) * 2016-02-05 2021-07-14 Inventisbio Llc Degradadores de los receptores de estrógenos selectivos y sus usos
US10125135B2 (en) 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
WO2018019793A1 (en) * 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
WO2018049042A1 (en) * 2016-09-07 2018-03-15 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancers by inhibiting estrogen signaling in myeloid-derived suppressor cells
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
JP6744489B2 (ja) 2016-10-24 2020-08-19 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 癌の治療において有用な６，７，８，９−テトラヒドロ−３Ｈ−ピラゾロ［４，３−ｆ］イソキノリン誘導体
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
JOP20190183B1 (ar) 2017-01-30 2022-09-15 Astrazeneca Ab معدِلات مستقبلات الاستروجين
US10208011B2 (en) 2017-02-10 2019-02-19 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
WO2019192533A1 (zh) * 2018-04-04 2019-10-10 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
EP3793608A4 (en) 2018-05-14 2022-04-20 Nuvation Bio Inc. COMPOUNDS TARGETING ANTICANCER NUCLEAR HORMONE RECEPTORS
CN118239948A (zh) 2018-06-21 2024-06-25 豪夫迈·罗氏有限公司 固体形式及制备稠合三环化合物的方法，包括其使用方法
CA3123321A1 (en) * 2018-12-24 2020-07-02 InventisBio Co., Ltd. Novel salts of selective estrogen receptor degraders
SG11202111402PA (en) * 2019-05-14 2021-11-29 Nuvation Bio Inc Anti-cancer nuclear hormone receptor-targeting compounds
CA3144791A1 (en) * 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
AU2021230588A1 (en) * 2020-03-06 2022-08-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
KR20230005270A (ko) 2020-04-24 2023-01-09 아스트라제네카 아베 약학적 제형
AU2021260829B2 (en) 2020-04-24 2024-01-11 Astrazeneca Ab Dosage regimen for the treatment of cancer
US11848549B2 (en) * 2020-09-15 2023-12-19 Easy Solar Products, Inc. Junction box with flashing for a tile surface
EP4267578A4 (en) 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS
WO2022166983A1 (zh) * 2021-02-08 2022-08-11 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
JP2024516024A (ja) 2021-05-03 2024-04-11 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
WO2023283329A1 (en) * 2021-07-08 2023-01-12 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2023091550A1 (en) * 2021-11-18 2023-05-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2023221122A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
CA3262155A1 (en) 2022-08-11 2024-02-15 Evexta Bio COMPOUNDS FOR CANCER TREATMENT
WO2024039860A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
WO2024039858A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
CA3262231A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
AU2023356291A1 (en) * 2022-10-05 2025-04-17 Novartis Ag Methods of treating estrogen receptor-mediated disorders
WO2024076633A1 (en) * 2022-10-05 2024-04-11 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
CN120322224A (zh) * 2022-12-09 2025-07-15 奥列马制药公司 雌激素受体拮抗剂的剂型
WO2025106890A1 (en) * 2023-11-17 2025-05-22 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
WO2025168601A1 (en) 2024-02-05 2025-08-14 Evexta Bio Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases
WO2025175249A1 (en) 2024-02-14 2025-08-21 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
DE69531476T2 (de) * 1994-09-12 2004-06-09 Lilly Industries Ltd., Basingstoke Serotonergische Modulatoren
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
ID24568A (id) 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6583170B1 (en) 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US20020016318A1 (en) 2000-07-06 2002-02-07 American Home Products Corporation Methods of treating breast disorders
BR0112360A (pt) 2000-07-06 2003-05-06 Wyeth Corp Método para aumentar a atividade da sintase de óxido nìtrico
WO2002003988A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
AR030064A1 (es) 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
CN1452497A (zh) 2000-07-06 2003-10-29 惠氏公司 Ssri和雌激素制剂的联合药物形式
JP2004502731A (ja) 2000-07-06 2004-01-29 ワイス スタチン、エストロゲン剤および所望によるエストロゲンの組み合わせ
AU2001271784A1 (en) 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
EP1299093A2 (en) 2000-07-06 2003-04-09 Wyeth Combinations of bisphosphonates, estrogenic agents and optionally estrogens
WO2002003990A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
AU2001271781A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating sphincter incontinence
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
ATE278421T1 (de) 2000-08-11 2004-10-15 Wyeth Corp Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
WO2003016270A2 (en) 2001-08-11 2003-02-27 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
EP1720862A1 (en) 2004-02-03 2006-11-15 Eli Lilly And Company Kinase inhibitors
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
AU2005222632B2 (en) * 2004-03-15 2012-02-09 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
AU2006206446A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
RU58668U1 (ru) 2006-06-05 2006-11-27 Открытое акционерное общество "Нижегородский машиностроительный завод" Водогрейный котел
PL2434891T3 (pl) 2009-05-27 2020-12-28 Ptc Therapeutics, Inc. Sposoby leczenia nowotworu złośliwego i stanów nienowotworowych
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
WO2010138706A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
HRP20170786T1 (hr) 2010-06-10 2017-08-11 Seragon Pharmaceuticals, Inc. Modulatori estrogenskog receptora i njihove uporabe
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
JP5886873B2 (ja) * 2010-12-24 2016-03-16 メルク・シャープ・エンド・ドーム・ベー・フェー Ｎ置換アゼチジン誘導体
MX357496B (es) * 2011-12-14 2018-07-11 Seragon Pharmaceuticals Inc Moduladores del receptor de estrógenos fluorados y sus usos.
AU2012353660A1 (en) 2011-12-16 2014-06-12 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
TN2015000516A1 (en) * 2013-05-28 2017-04-06 Astrazeneca Ab Chemical compounds
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
UA117249C2 (uk) * 2013-06-19 2018-07-10 Серагон Фармасьютікалз, Інк. Модулятор рецептора естрогену та його застосування
CN107110482A (zh) * 2014-10-23 2017-08-29 Mtg－梅尔特朗有限公司 用于危险区域的照明装置
JP6266177B2 (ja) * 2014-10-31 2018-01-24 カーステン マニュファクチュアリング コーポレーション ゴルフクラブヘッドの溝及びゴルフクラブヘッドの溝を製造する方法
JP2017538727A (ja) 2014-12-18 2017-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌の治療に有用な２，３−ジフェニルクロメンの誘導体
EP3233828B1 (en) 2014-12-18 2020-03-04 F. Hoffmann-La Roche AG Estrogen receptor modulators and uses thereof
EA032311B1 (ru) * 2014-12-18 2019-05-31 Ф. Хоффманн-Ля Рош Аг Тетрагидро-пиридо[3,4-b]индоловые модуляторы эстрогеновых рецепторов и их применение
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
HUE055321T2 (hu) 2015-10-01 2021-11-29 Olema Pharmaceuticals Inc Tetrahidro-1H-pirido[3,4-b]indol anti-ösztrogén hatóanyagok
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
CN109843882A (zh) 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
JP6744489B2 (ja) 2016-10-24 2020-08-19 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 癌の治療において有用な６，７，８，９−テトラヒドロ−３Ｈ−ピラゾロ［４，３−ｆ］イソキノリン誘導体
MY210254A (en) 2018-07-12 2025-09-04 Lilly Co Eli Selective estrogen receptor degraders
TWI702219B (zh) 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
KR20180071274A (ko) 2018-06-27
KR102710603B1 (ko) 2024-09-27
CA3000410A1 (en) 2017-04-06
EP3355884A1 (en) 2018-08-08
IL286518A (en) 2021-10-31
SI3355884T1 (sl) 2021-11-30
AU2016331065A1 (en) 2018-04-26
US11229630B2 (en) 2022-01-25
JP2021001231A (ja) 2021-01-07
PL3355884T3 (pl) 2021-11-29
MX2021005214A (es) 2021-06-18
IL258363B (en) 2021-10-31
CN108366996A (zh) 2018-08-03
IL286518B2 (en) 2024-06-01
KR20240142622A (ko) 2024-09-30
ES2881398T3 (es) 2021-11-29
US20210059991A1 (en) 2021-03-04
JP2018530549A (ja) 2018-10-18
BR112018006121A2 (pt) 2018-10-23
IL258363A (en) 2018-05-31
EP3912680A1 (en) 2021-11-24
LT3355884T (lt) 2021-07-26
RU2021107754A (ru) 2021-04-01
US11672785B2 (en) 2023-06-13
CY1124669T1 (el) 2022-07-22
MX382269B (es) 2025-03-13
MX2018003929A (es) 2018-11-22
IL286518B1 (en) 2024-02-01
US10292971B2 (en) 2019-05-21
BR122023020677A2 (pt) 2023-12-12
AU2021206861A1 (en) 2021-08-12
AU2023202620A1 (en) 2023-05-18
EP3355884B1 (en) 2021-04-28
NZ741130A (en) 2024-11-29
CL2018000827A1 (es) 2018-09-28
EP3355884A4 (en) 2019-06-05
US20180289679A1 (en) 2018-10-11
SMT202100433T1 (it) 2021-09-14
US20220370421A1 (en) 2022-11-24
US20190247372A1 (en) 2019-08-15
AU2016331065B2 (en) 2021-04-29
RS62133B1 (sr) 2021-08-31
PT3355884T (pt) 2021-07-26
JP6776348B2 (ja) 2020-10-28
IL310489A (en) 2024-03-01
JP7650316B2 (ja) 2025-03-24
DK3355884T3 (da) 2021-08-02
BR112018006121B1 (pt) 2024-01-23
US20240131013A1 (en) 2024-04-25
AU2025203540A1 (en) 2025-06-05
UA122346C2 (uk) 2020-10-26
NZ779654A (en) 2024-12-20
HUE055321T2 (hu) 2021-11-29
CN108366996B (zh) 2021-04-09
WO2017059139A1 (en) 2017-04-06
JP7277424B2 (ja) 2023-05-19
US20240226073A9 (en) 2024-07-11
RU2745742C1 (ru) 2021-03-31
AU2023202620B2 (en) 2025-02-27
JP2023087106A (ja) 2023-06-22
US10624878B2 (en) 2020-04-21
AU2021206861B2 (en) 2023-02-02
HRP20211124T1 (hr) 2021-10-15

Similar Documents

Publication Publication Date Title
CN108366996B (zh) 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物
JP7348665B2 (ja) 選択的エストロゲン受容体分解剤としての置換ベンゾチオフェン類似体
TWI858082B (zh) 吲唑類衍生物、其製備方法及其在醫藥上的應用
WO2019192533A1 (zh) 用于治疗乳腺癌的雌激素受体降解剂
CN117956996A (zh) 用于yap/tead调节的化合物和方法及其适应证
HK40056233A (en) Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
JP7098826B2 (ja) ピリミジニル－ヘテロアリールオキシ－ナフチル化合物および使用方法
HK1259498B (en) Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
WO2019015689A1 (zh) 手性3-奎宁环酮类化合物、制备方法及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40056233

Country of ref document: HK